JMIR Mental Health (Oct 2022)

An App-Based Digit Symbol Substitution Test for Assessment of Cognitive Deficits in Adults With Major Depressive Disorder: Evaluation Study

  • Roger S McIntyre,
  • Orly Lipsitz,
  • Nelson B Rodrigues,
  • Mehala Subramaniapillai,
  • Flora Nasri,
  • Yena Lee,
  • Ben Fehnert,
  • James King,
  • Lambros Chrones,
  • Kevin Kratiuk,
  • Sharif Uddin,
  • Joshua D Rosenblat,
  • Rodrigo B Mansur,
  • Maggie McCue

DOI
https://doi.org/10.2196/33871
Journal volume & issue
Vol. 9, no. 10
p. e33871

Abstract

Read online

BackgroundCognitive dysfunction is an impairing core symptom of depression. Among adults with major depressive disorder (MDD) treated with antidepressants, residual cognitive symptoms interfere with patient-reported outcomes. The foregoing characterization of cognitive symptoms provides the rationale for screening and assessing the severity of cognitive symptoms at point of care. However, clinical neurocognitive assessments are time-consuming and difficult, and they require specialist expertise to interpret them. A smartphone-delivered neurocognitive test may offer an effective and accessible tool that can be readily implemented into a measurement-based care framework. ObjectiveWe aimed to evaluate the use of a smartphone-delivered app-based version of the established Cognition Kit Digit Symbol Substitution Test (DSST) neurocognitive assessment compared to a traditional paper-and-pencil version. MethodsConvergent validity and test-retest reliability of the 2 versions were evaluated. Patient satisfaction with the app was also assessed. ResultsAssessments made using the app-based Cognition Kit DSST were highly correlated with the standard paper-and-pencil version of the test, both at the baseline visit (r=0.69, df=27; P<.001) and at the end-of-study visit (r=0.82, df=27; P<.001), and they were positively evaluated by 30 patients as being user-friendly, easy to navigate, and preferable over the paper-and-pencil version of the DSST. However, although the app-based Cognition Kit DSST was validated in patients with MDD, it still needs to be evaluated in healthy controls. ConclusionsApp-based DSST may facilitate a more personalized, convenient, and cost-effective method of cognitive assessment, helping to guide measurement-based care and psychotherapeutic and pharmacologic treatment options for patients with MDD. Trial RegistrationClinicalTrials.gov NCT03999567; https://tinyurl.com/2p8pnyv7